No products in the cart.

Human Clusterin ELISA kit

SKU Product Brand Unit Availability Price Quantity  
EK-07-0180
Human Clusterin ELISA kit
Erpan Tech In stock

Specifications        

Product Cat#: EK-07-0180
Product name: Human Clusterin ELISA kit
Target Name: CLU
Species Reactivity: Human
Product Size: 48/96 Tests
Sensitivity: 1.38 ng/mL
Assay range: 10-250 ng/mL
Assay Time: 90 minutes
Platform: Colorimetric Microplate Reader
Conjugate: HRP
ELISA Type: Competitive ELISA
Detection Method: Colorimetric
Storage temperature: Store at 2-8°C
Stability: Stable within the expiration date under suggested storage conditions
Shipping condition: Wet ice
Kit Contents: Microtiter plate ( 1x ), Enzyme conjugate ( 1 vial ), Standard samples ( 6 vials ),
Substrates ( A & B, 2 vials ), Stop solution ( 1 vial ), Wash Solution ( 100x, 1 vial ),
Balance solution ( 1 vial ), Instruction ( 1 copy )
Other Names of Target: Clusterin, AAG4, APO-J, APOJ, CLI, CLU1, CLU2, KUB1, NA1/NA2, SGP-2, SGP2, SP-40, TRPM-2, TRPM2, Clusterin
Show More

Target information

Clusterin (apolipoprotein J) is a 75 – 80 kDa disulfide-linked heterodimeric protein associated with the clearance of cellular debris and apoptosis.In humans, clusterin is encoded by the CLU gene on chromosome 8.CLU is a molecular chaperone responsible for aiding protein folding of secreted proteins, and its three isoforms have been differentially implicated in pro- or antiapoptotic processes. Through this function, CLU is involved in many diseases related to oxidative stress, including neurodegenerative diseases, cancers, inflammatory diseases, and aging.CLU may promote tumorigenesis by facilitating BAX-KLU70 binding and, consequently, preventing BAX from localizing to the outer mitochondrial membrane to stimulate cell death. In clear cell renal cell carcinoma, CLU functions to regulate ERK 1/2 signaling and matrix metallopeptidase-9 expression to promote tumor cell migration, invasion, and metastasis. In epithelial ovarian cancer, CLU has been observed to promote angiogenesis and chemoresistance. Other pathways CLU participates in to downplay apoptosis in tumor cells include the PI3K/AKT/mTOR pathway and NF-κB pathway. Interestingly, unlike most other cancers, which feature upregulated CLU levels to enhance tumor cell survival, testicular seminoma features downregulated CLU levels, allowing for increased sensitivity to chemotherapy treatments. Other cancers CLU has been implicated in include breast cancer, pancreatic cancer, hepatocellular carcinoma, and melanoma.

Provider

Erpantech Laboratory

Download

MSDS-EK-07-0180.pdf (232 downloads )